Aulos Bioscience Receives HREC Approval to Initiate First-in-Human Clinical Trial Evaluating Anti-Tumor Activity of Novel IL-2 Therapeutic AU-007
Press release content from Business Wire. The AP news staff was not involved in its creation.
Stay updated with breaking news from Aron Knickerbocker. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Aulos Bioscience Appoints Leo Redmond as Chief Financial Officer News provided by Share this article Share this article LARKSPUR, Calif., May 17, 2021 /PRNewswire/ -- Aulos Bioscience, a biotechnology company developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors, announced today that Leo Redmond will join the company as chief financial officer. Redmond brings to Aulos nearly three decades of financial experience in the biopharmaceutical industry. He will be based in the company's new headquarters in Larkspur, California. "We a...
Aulos Bioscience Appoints Aron Knickerbocker as CEO News provided by Share this article Share this article BOSTON and TEL AVIV, Israel, March 15, 2021 /PRNewswire/ -- Aulos Bioscience, a biotechnology company that is developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors, announced today that Aron Knickerbocker has joined the company as its chief executive officer and a member of its board of directors, effective immediately. Yanay Ofran, Ph.D., CEO of Biolojic Design and co-founder and founding CEO of Aulos, will continue to s...